ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting

Podiatry Arena ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

21st October 2008, 03:10 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,060

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting

Podiatry Arena members do not see these ads

Roche announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) have been accepted for presentation at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place October 24-29 in San Francisco. These studies evaluate ACTEMRA, a novel treatment targeting interleukin-6 (IL-6) receptors, in patients with moderately to severely active RA.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Australasian College of Podiatric Surgeons Annual Symposium 2008	LuckyLisfranc	Conferences	2	24th July 2008 03:19 PM
AMA meeting: Physicians demand greater oversight of doctors of nursing	NewsBot	American Medical Association News	0	29th June 2008 06:00 PM
Incidence of and risk factors for nodding off at scientific sessions	Admin	Break Room	4	26th January 2006 03:59 AM
Rheumatology Guidelines	Mandyyorke	United Kingdom	1	6th November 2005 01:13 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 07:18 AM.

User Name		Remember Me?
Password